Articles related to GUIDELINES/RECOMMENDATIONS

A layered approach to care is described with lifestyle interventions being a key feature of the updated recommendations. The recommendations now include therapies proven to improve cardiovascular and kidney outcomes in patients with diabetes and CKD.

Beyond the strong recommendation for bisphosponates as initial medical therapy in postmenopausal women with osteoporosis, the updated guidelines also suggest (not recommend) denosumab as second line therapy in women, bisphosphonates for osteoporosis in men, and romosozumab in women with very high risk of fractures. For the complete updated guideline, see Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.

The updated ADA standards have several significant changes. These include: A revised definition of HTN to match that of the ACC and AHA New recommendations for statin use Changes to recommendations around CKD treatment Revised weight loss goals Use of diabetes technology And much more

The updated AAP guidance “recommends programmatic consideration of providing more than 5 consecutive doses of palivizumab depending on the duration of the current RSV surge in a given region of the country.”

Patients discontinuing antidepressant therapy experience insomnia, flu-like symptoms, mood disturbances, dizziness, and paresthesias — among a broad array of adverse effects. Those symptoms can last for days to months. This narrative review describes the array of discontinuation symptoms and their causes and provides practical clinical guidance for discontinuing antidepressants to minimize the risk of antidepressant discontinuation syndrome (ADS).

This update is based on the results from the June 2022 ATHENA-MONO2 phase III multinational, double-blind, randomized controlled trial (RCT), which showed a significant improvement in progression-free survival (PFS) in patients with stage III-IV epithelial ovarian cancer (EOC) who are in complete or partial response to first-line platinum-based chemotherapy.